Literature DB >> 24024021

Serum interleukins 6 and 8 in mild and severe asthmatic patients, is it difference?

Javad Ghaffari1, Ali Reza Rafiei, Abolghasem Ajami, Mohammadreza Mahdavi, Bahareh Hoshiar.   

Abstract

BACKGROUND: About 5-10% of patients with asthma suffer from poorly-controlled disease despite corticosteroid (CS) therapy.
METHODS: 21 severe and 30 mild asthma patients were recruited and underwent collection of blood sample. We determined whether there were any differences in inflammatory biomarkers between severe and mild asthma patients or not.
RESULTS: Levels of Interleukin-8 (IL-8) and Interleukin-6 (IL-6) in blood supernatants were similar in both groups of asthma patients. Leukocytes were in range of normal in all patients. Increased eosinophil was in 29% of severe cases and 23% in mild cases. IgE level was increased in 43% of severe form and 50% in mild form.
CONCLUSION: There is not any difference between severe and mild asthma in serum IL-8 and IL-6. Therefore, level of serum cytokines may not predict severity of asthma.

Entities:  

Keywords:  Interleukin 6; Interleukin8; Mild asthma; Severe asthma

Year:  2011        PMID: 24024021      PMCID: PMC3766940     

Source DB:  PubMed          Journal:  Caspian J Intern Med        ISSN: 2008-6164


  13 in total

Review 1.  Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society.

Authors:  K F Chung; P Godard; E Adelroth; J Ayres; N Barnes; P Barnes; E Bel; P Burney; P Chanez; G Connett; C Corrigan; J de Blic; L Fabbri; S T Holgate; P Ind; G Joos; H Kerstjens; P Leuenberger; C G Lofdahl; S McKenzie; H Magnussen; D Postma; M Saetta; S Salmeron; P Sterk
Journal:  Eur Respir J       Date:  1999-05       Impact factor: 16.671

Review 2.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

3.  Cellular infiltration of the airways in asthma of varying severity.

Authors:  M Synek; R Beasley; A J Frew; D Goulding; L Holloway; F C Lampe; W R Roche; S T Holgate
Journal:  Am J Respir Crit Care Med       Date:  1996-07       Impact factor: 21.405

4.  Pathological changes according to the severity of asthma.

Authors:  S H Cho; J Y Seo; D C Choi; H J Yoon; Y J Cho; K U Min; G K Lee; J W Seo; Y Y Kim
Journal:  Clin Exp Allergy       Date:  1996-10       Impact factor: 5.018

Review 5.  Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases.

Authors:  H Yssel; H Groux
Journal:  Int Arch Allergy Immunol       Date:  2000-01       Impact factor: 2.749

6.  High sensitivity C-reactive protein in asthma.

Authors:  M Takemura; H Matsumoto; A Niimi; T Ueda; H Matsuoka; M Yamaguchi; M Jinnai; S Muro; T Hirai; Y Ito; T Nakamura; T Mio; K Chin; M Mishima
Journal:  Eur Respir J       Date:  2006-05       Impact factor: 16.671

7.  Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients.

Authors:  I Godoy; A O Campana; R R C Geraldo; C R Padovani; S A R Paiva
Journal:  Eur Respir J       Date:  2003-12       Impact factor: 16.671

8.  IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells.

Authors:  T Aarvak; M Chabaud; P Miossec; J B Natvig
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

Review 9.  Interleukin-17.

Authors:  F Fossiez; J Banchereau; R Murray; C Van Kooten; P Garrone; S Lebecque
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

10.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.

Authors:  F Fossiez; O Djossou; P Chomarat; L Flores-Romo; S Ait-Yahia; C Maat; J J Pin; P Garrone; E Garcia; S Saeland; D Blanchard; C Gaillard; B Das Mahapatra; E Rouvier; P Golstein; J Banchereau; S Lebecque
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  2 in total

1.  Elevated Serum Interleukin-8 Level as a Preferable Biomarker for Identifying Uncontrolled Asthma and Glucocorticosteroid Responsiveness.

Authors:  Jingxi Zhang; Chong Bai
Journal:  Tanaffos       Date:  2017-06

2.  Benefits of omalizumab on anxiety and depression in patients with severe asthma.

Authors:  Fatih Uzer; Omer Ozbudak
Journal:  Caspian J Intern Med       Date:  2018
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.